We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company
LJPC

Delisted

LJPC was delisted on the 19th of August, 2022.

Back to rankings

95 hedge funds and large institutions have $828M invested in La Jolla Pharmaceutical Company in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

15% more capital invested

Capital invested by funds: $718M → $828M (+$111M)

14% more funds holding

Funds holding: 83 → 95 (+12)

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

88% less call options, than puts

Call options by funds: $5.35M | Put options by funds: $44M

Holders
95
Holders Change
+12
Holders Change %
+14.46%
% of All Funds
2.37%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
24
Increased
29
Reduced
26
Closed
10
Calls
$5.35M
Puts
$44M
Net Calls
-$38.6M
Net Calls Change
-$45.1M

Top Buyers

Rank Fund Capital Flow
1
ORI
Oak Ridge Investments
Illinois
+$13.5M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.58M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$6.26M
5
CS
Candriam SCA
Luxembourg
+$5.82M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$25.2M
2
State Street
State Street
Massachusetts
-$14M
3
BBA
Baker Bros. Advisors
New York
-$11.3M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.62M
5
BC
Broadfin Capital
New York
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
51
Hudson Bay Capital Management
Connecticut
$696K +$643K +20,000 New
UBS Group
52
UBS Group
Switzerland
$667K -$307K -9,552 -33%
Parallax Volatility Advisers
53
Parallax Volatility Advisers
California
$655K +$606K +18,833 New
BCM
54
BlueCrest Capital Management
Jersey
$642K +$593K +18,454 New
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$636K – – –
Millennium Management
56
Millennium Management
New York
$596K +$551K +17,140 New
Wells Fargo
57
Wells Fargo
California
$593K +$3.83K +119 +0.7%
NPC
58
National Planning Corporation
California
$562K -$41K -1,275 -7%
AAM
59
Advisors Asset Management
Colorado
$526K -$577K -17,940 -54%
CG
60
Cutler Group
California
$480K +$187K +5,813 +73%
VF
61
Virtu Financial
New York
$456K +$421K +13,104 New
State of Wisconsin Investment Board
62
State of Wisconsin Investment Board
Wisconsin
$452K – – –
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$449K -$15.1K -470 -4%
TD Asset Management
64
TD Asset Management
Ontario, Canada
$449K +$415K +12,900 New
MLICM
65
Metropolitan Life Insurance Company (MetLife)
New York
$433K – – –
Citigroup
66
Citigroup
New York
$426K -$1.02M -31,830 -72%
VEA
67
Virtus ETF Advisers
New York
$412K +$34.9K +1,084 +10%
AIG
68
American International Group
New York
$408K +$28.2K +876 +8%
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$393K – – –
KAM
70
Kazazian Asset Management
Florida
$382K +$353K +10,992 New
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$379K +$347K +10,799 +10,799%
Barclays
72
Barclays
United Kingdom
$348K -$112K -3,477 -26%
NFA
73
Nationwide Fund Advisors
Ohio
$335K -$10.7K -334 -3%
GCP
74
GSA Capital Partners
United Kingdom
$309K +$286K +8,892 New
JCM
75
Jafra Capital Management
New York
$308K +$1.19K +37 +0.4%
1 2
3
4 5

LJPC Hedge Fund Activity: Q3 2017 in Review

95 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2017, worth a combined $828M — up 15% from $718M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LJPC positions and 10 closed out — a net gain of 14 holders — while 29 added to existing stakes and 26 trimmed.

The largest buyer was Oak Ridge Investments, opening a new position worth an estimated $13.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $25.2M sold.

  • 95 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2017, up from 83 in Q2 2017.
  • Funds reported $828M of La Jolla Pharmaceutical Company stock for Q3 2017, up 15% quarter-over-quarter.
  • 24 funds opened new La Jolla Pharmaceutical Company positions in Q3 2017 and 10 closed out, a net change of +14 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q3 2017 was Oak Ridge Investments, an estimated $13.5M added.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2017 was Janus Henderson Group, an estimated $25.2M sold.

Based on aggregated 13F filings for Q3 2017.